IOL Chemicals and Pharmaceuticals Limited has announced its unaudited financial results for the quarter and nine months ended 31st December 2025, demonstrating steady operational performance across key financial metrics. The company published these results in leading newspapers on 12th February 2026, in compliance with SEBI regulations.

Financial Performance Overview

The company's financial performance for the third quarter of FY26 shows consistent growth patterns. Total income from operations reached ₹585.68 crore for the quarter ended 31st December 2025, representing an increase from ₹527.37 crore in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine-month period ended 31st December 2025, IOL Chemicals reported robust financial metrics across both standalone and consolidated operations. The company achieved total income from operations of ₹1719.15 crore compared to ₹1569.31 crore in the corresponding nine-month period of the previous year.

Capital Structure and Dividend Declaration

The company maintains a stable capital structure with equity share capital of ₹58.71 crore and other equity reserves of ₹1713.13 crore as of 31st December 2025. The Board of Directors has declared an interim dividend of ₹1 per equity share having face value of ₹2 each for the financial year 2025-26. The record date for determining dividend entitlement has been fixed as 17th February 2026.

Regulatory Compliance and Approvals

The unaudited financial results were reviewed and recommended by the Audit Committee to the Board of Directors and subsequently approved by the Board at their meeting held on 11th February 2026. The financial results have been subjected to limited review by the company's statutory auditors, who issued an unmodified report. These results were filed with stock exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Consolidated vs Standalone Performance

Both standalone and consolidated financial results show similar performance patterns, indicating consistent operational efficiency across the group. The consolidated figures closely mirror standalone performance, with total income from operations at ₹585.68 crore for Q3 FY26 and ₹1719.15 crore for the nine-month period, demonstrating the company's focused business approach.

IOL Chemicals & Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, through a regulatory filing on February 11, 2026. The Board of Directors approved the results at their meeting held on the same day, which commenced at 1:15 PM and concluded at 2:31 PM.

Q3 FY26 Financial Performance

The company reported steady financial performance for the quarter ended December 31, 2025. The standalone financial results showed consistent operational metrics across key parameters.

Nine Months Performance

For the nine months period ended December 31, 2025, the company demonstrated strong growth momentum across all key financial parameters.

Segment-wise Performance

The company operates through two primary segments - Pharmaceuticals and Chemicals. For Q3 FY26, the pharmaceutical segment generated revenue of ₹356.05 crore compared to ₹300.58 crore in Q3 FY25, while the chemical segment recorded ₹287.82 crore against ₹275.14 crore in the corresponding previous quarter.

Interim Dividend Declaration

The Board of Directors declared an interim dividend of ₹1 per equity share (50%) having face value of ₹2 each for the financial year 2025-26. The company has fixed February 17, 2026 as the record date to determine eligible shareholders for the interim dividend payment.

Exceptional Items and Corporate Developments

The company reported exceptional items worth ₹11.21 crore in Q3 FY26, primarily arising from changes in wage definition following the notification of four Labour Codes by the Government of India on November 21, 2025. During the quarter, the Board approved the closure of IOL Life Sciences Limited, a wholly owned subsidiary, through striking off from the Register of Companies. Additionally, the company incorporated IOL Pharmaxis UK Limited in the United Kingdom on October 16, 2025, though business operations have not yet commenced.

Auditor Certification

The financial results received an unmodified review report from statutory auditors Ashwani & Associates, Chartered Accountants. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and comply with SEBI listing regulations. The company confirmed that both standalone and consolidated results are available on its website at www.iolcp.com .